GW&K Investment Management LLC lessened its position in Catalent Inc (NYSE:CTLT) by 2.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,846,968 shares of the company’s stock after selling 41,266 shares during the quarter. Catalent makes up about 1.1% of GW&K Investment Management LLC’s investment portfolio, making the stock its 8th largest holding. GW&K Investment Management LLC owned about 1.27% of Catalent worth $57,588,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Catalent by 9.4% during the third quarter. Vanguard Group Inc. now owns 12,925,639 shares of the company’s stock valued at $588,763,000 after buying an additional 1,110,779 shares during the last quarter. Vanguard Group Inc raised its stake in Catalent by 9.4% during the third quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock valued at $588,763,000 after buying an additional 1,110,779 shares during the last quarter. BlackRock Inc. raised its stake in Catalent by 7.0% during the third quarter. BlackRock Inc. now owns 12,628,951 shares of the company’s stock valued at $575,248,000 after buying an additional 822,258 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Catalent by 29.5% during the third quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock valued at $363,316,000 after buying an additional 1,819,020 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in Catalent by 13.0% during the third quarter. Janus Henderson Group PLC now owns 7,234,661 shares of the company’s stock valued at $329,539,000 after buying an additional 833,924 shares during the last quarter. Institutional investors and hedge funds own 97.95% of the company’s stock.

Catalent stock opened at $42.03 on Tuesday. The firm has a market capitalization of $6.12 billion, a price-to-earnings ratio of 26.43, a price-to-earnings-growth ratio of 2.26 and a beta of 1.66. Catalent Inc has a 12 month low of $29.23 and a 12 month high of $46.43. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.08 and a quick ratio of 1.63.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, February 5th. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.08. Catalent had a return on equity of 17.42% and a net margin of 5.48%. The company had revenue of $623.00 million during the quarter, compared to analyst estimates of $608.38 million. During the same quarter in the previous year, the company posted $0.45 earnings per share. Catalent’s revenue was up 2.8% compared to the same quarter last year. Equities research analysts forecast that Catalent Inc will post 1.69 earnings per share for the current year.

CTLT has been the subject of a number of recent research reports. Zacks Investment Research upgraded Catalent from a “sell” rating to a “hold” rating in a research note on Tuesday, October 30th. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. First Analysis raised Catalent from a “neutral” rating to an “outperform” rating and reduced their target price for the stock from $47.00 to $43.00 in a report on Wednesday, November 7th. Royal Bank of Canada set a $44.00 target price on Catalent and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, TheStreet lowered Catalent from a “b-” rating to a “c+” rating in a report on Wednesday, November 7th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $47.13.

ILLEGAL ACTIVITY NOTICE: “GW&K Investment Management LLC Has $57.59 Million Stake in Catalent Inc (CTLT)” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://theolympiareport.com/2019/02/19/gwk-investment-management-llc-has-57-59-million-stake-in-catalent-inc-ctlt.html.

Catalent Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Article: How to Profit and Limit Losses With Stop Orders

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.